U.S. markets closed

BriaCell Therapeutics Corp. (BCTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.91-0.21 (-3.43%)
At close: 04:00PM EST
5.91 0.00 (0.00%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close6.12
Bid5.89 x 1100
Ask5.91 x 1800
Day's Range5.64 - 6.19
52 Week Range2.81 - 12.47
Avg. Volume1,543,986
Market Cap95.732M
Beta (5Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-0.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BCTX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BriaCell Therapeutics Corp.
    Analyst Report:, provides enterprise cloud computing solutions, including Sales Cloud, the company’s main customer relationship management software-as-a-service product. also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

    NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), is pleased to announce that all resolutions proposed to shareholders at the Annual and Special Meeting of Shareholders (the “Meeting”) held virtually via teleconference on January 18, 2022 were passed. Voting for each of the director nominees was as follows: NomineeForWithheldActualPercentageActualPercentageDr. William V. Williams

  • CNW Group

    TMX Group Equity Financing Statistics - December 2021

    TMX Group today announced its financing activity on Toronto Stock Exchange and TSX Venture Exchange for December 2021.

  • Zacks Small Cap Research

    BCTX: Game, Set and Match: HLAs Score Success

    By John Vandermosten, CFA NASDAQ:BCTX READ THE FULL BCTX RESEARCH REPORT We are initiating coverage of BriaCell Therapeutics Corp. (NASDAQ:BCTX). This value is based on our estimates for a successful development and commercialization of Bria-IMT for advanced breast cancer. The candidate is expected to be submitted to the FDA in 2024 and receive approval in 2025. We forecast pivotal studies and